TITLE:
The FLASH Study: A Study of Roflumilast Versus Placebo in Patients With Asthma (BY217/M2-023)

CONDITION:
Asthma

INTERVENTION:
Roflumilast

SUMMARY:

      The purpose of this study is to confirm the dose of roflumilast to be used for asthma
      management by comparing the effects of 250 mcg and 500 mcg oral roflumilast with placebo on
      pulmonary function and asthma symptoms.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Main Inclusion Criteria:

          -  Diagnosis of persistent chronic bronchial asthma

          -  Baseline lung function within specified parameters

          -  No change in asthma treatment during the last 4 weeks prior to start of baseline
             period

          -  Stable clinical state

          -  Except for asthma, in good health

          -  Non-smokers or ex-smokers

        Main Exclusion Criteria:

          -  Poorly controlled asthma

          -  Diagnosis of chronic pulmonary disease and/or other relevant lung diseases

          -  Patients using continuously (more than 3 days per week) > 8 puffs/day rescue
             medication
      
